Enclomiphene Citrate vs Testosterone Enanthate: Cost and Access Head-to-Head

How These Two Drugs Work Differently

Enclomiphene citrate and testosterone enanthate both raise serum testosterone, but through opposite mechanisms. Testosterone enanthate is exogenous testosterone injected into muscle or subcutaneous tissue, directly replacing what the testes are not producing. It signals the hypothalamus and pituitary to shut down luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which suppresses sperm production in most men within 3 to 6 months 1.

Enclomiphene works upstream. It is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus. This causes the pituitary to release more LH and FSH, stimulating the testes to produce both testosterone and sperm. Kim et al. demonstrated in a 2016 study (N=48) that enclomiphene restored serum testosterone to eugonadal levels while maintaining sperm concentration and motility in men with secondary hypogonadism 2. That distinction matters enormously for cost-access decisions, because it determines which men are even candidates for each drug.

Monthly Cost: What You Actually Pay

Testosterone enanthate wins on price. A 5 mL vial of 200 mg/mL generic testosterone enanthate (enough for roughly 5 weekly doses of 200 mg) costs $40 to $90 at most retail pharmacies without insurance, according to GoodRx cash-price aggregation as of early 2026. With commercial insurance, copays typically fall between $10 and $30 per month. The FDA-approved labeling for testosterone enanthate lists intramuscular injection every 1 to 4 weeks, and most TRT protocols settle on weekly or biweekly dosing, keeping monthly supply costs low.

Enclomiphene citrate has no FDA-approved product on the U.S. market for male hypogonadism. Androxal (the branded formulation) completed Phase III trials but was never approved. Men who use enclomiphene today obtain it through 503A or 503B compounding pharmacies, often coordinated by telehealth platforms. Cash prices typically run $90 to $180 per month depending on the pharmacy, dose (12.5 mg to 25 mg daily), and subscription model.

Syringes, alcohol swabs, and sharps containers for testosterone enanthate add roughly $5 to $15 per month. That narrows the gap slightly but does not close it. The total monthly spend comparison looks like this: testosterone enanthate with insurance runs $15 to $45 all-in, while enclomiphene through a telehealth compounding pathway runs $90 to $180 with no insurance offset.

Insurance Coverage and Formulary Status

Testosterone enanthate appears on the formularies of virtually every major U.S. insurer. Medicare Part D, Medicaid, Tricare, and commercial plans from UnitedHealthcare, Aetna, Cigna, and Blue Cross Blue Shield all cover generic testosterone enanthate, typically at Tier 1 or Tier 2 copay levels. Prior authorization requirements vary: some plans require two morning serum testosterone levels below 300 ng/dL, documented symptoms, and confirmation that the patient is not seeking fertility 3.

Enclomiphene has no National Drug Code (NDC) tied to an FDA-approved product for this indication. Compounded medications are generally excluded from formulary coverage. Some patients have obtained partial reimbursement by submitting claims with clomiphene citrate NDCs, but this is inconsistent and carrier-dependent. The practical reality: if insurance coverage is a deciding factor, testosterone enanthate is the default choice.

The American Urological Association's 2018 guidelines on testosterone therapy acknowledge SERMs as an off-label option for men who wish to preserve fertility but stop short of recommending them as first-line therapy 4. Without guideline endorsement as primary treatment, insurers have little incentive to add compounded enclomiphene to formularies.

Pharmacy Access and Prescribing Logistics

Walk into any CVS, Walgreens, or Walmart pharmacy with a valid prescription, and testosterone enanthate is on the shelf. The drug has been manufactured continuously since the 1950s. Supply chain disruptions are rare.

Enclomiphene requires more effort. Patients typically need a prescription routed to a compounding pharmacy, either a local 503A pharmacy or a national 503B outsourcing facility. Shipping adds 2 to 7 business days. Telehealth men's health platforms (Hone, Defy Medical, Marek Health, among others) have simplified the pipeline by bundling consultation, lab review, and pharmacy fulfillment, but the process remains less straightforward than picking up a vial at a retail counter.

Testosterone enanthate carries Schedule III controlled-substance classification under the Controlled Substances Act. Prescribers must hold an active DEA registration, prescriptions cannot be called in to pharmacies in most states (they require e-prescribing or a written script), and refills are limited. Some states impose additional monitoring mandates.

Enclomiphene is not a controlled substance. Any licensed prescriber can write for it without DEA restrictions. Refills face no federal limits. For telemedicine prescribers operating across state lines, the absence of controlled-substance requirements removes a significant regulatory barrier.

The Fertility Factor in Cost Calculations

Cost-access comparisons between these drugs are incomplete without addressing fertility. The T-Trials, a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with testosterone levels below 275 ng/dL. Testosterone gel improved sexual function, physical function, and vitality scores over 12 months 1. The trials did not measure spermatogenesis, but exogenous testosterone's suppressive effect on sperm production is well established across decades of contraceptive research. Recovery of spermatogenesis after discontinuing TRT takes 6 to 24 months in most men, and some never fully recover 5.

For a 28-year-old man who wants children in the next 2 to 5 years, the "cheaper" option becomes expensive fast if it requires adding human chorionic gonadotropin (hCG) at $100 to $300 per month to maintain fertility, or if it leads to a $15,000 to $30,000 course of assisted reproduction because of iatrogenic azoospermia. Dr. John Amory, a professor of medicine at the University of Washington, has stated: "Prescribing testosterone to a young man without discussing its impact on fertility is a medical error we still see far too often."

Kim et al. showed that enclomiphene citrate raised testosterone from a mean of 228 ng/dL to 451 ng/dL at 3 months while sperm concentration actually increased from baseline 2. For fertility-minded men, the $90-$180 monthly cost of enclomiphene may represent a net savings compared to testosterone enanthate plus fertility-preservation add-ons.

Monitoring Costs and Long-Term Expense

Both drugs require periodic blood work. The Endocrine Society's 2018 clinical practice guideline recommends checking testosterone levels, hematocrit, PSA, and lipids at 3 months, 6 months, and annually thereafter for men on testosterone replacement therapy 6. Hematocrit monitoring is particularly important because testosterone enanthate raises red blood cell mass, with erythrocytosis (hematocrit above 54%) occurring in 3% to 18% of treated men depending on dose and route.

Enclomiphene does not cause erythrocytosis. It does not suppress the hypothalamic-pituitary-gonadal axis. Monitoring for men on enclomiphene typically involves testosterone, LH, FSH, estradiol, and a basic metabolic panel. The lab draw itself costs roughly the same ($50 to $200 per panel without insurance), but the frequency and clinical urgency differ. A man whose hematocrit climbs to 52% on testosterone enanthate may need therapeutic phlebotomy ($75 to $250 per session) or dose reduction with repeat labs. These downstream costs are rarely included in monthly price comparisons.

Over a 5-year horizon, the cumulative cost picture tightens. Testosterone enanthate's lower monthly drug cost is partially offset by higher monitoring intensity, phlebotomy visits, and the potential need for hCG co-therapy. Enclomiphene's higher drug cost is offset by simpler monitoring and no fertility add-ons.

Who Gets Prescribed What: Access by Provider Type

Primary care physicians and endocrinologists prescribe testosterone enanthate routinely. The drug has decades of prescribing data, clear FDA labeling, and established guidelines. Most providers are comfortable initiating and managing it.

Enclomiphene occupies a different niche. Urologists and reproductive endocrinologists are the specialists most likely to prescribe it, particularly for younger men with secondary hypogonadism and fertility concerns. The telehealth men's health sector has expanded access significantly since 2022, but the prescribing knowledge base remains narrower. A 2023 survey published in the Journal of Urology found that only 42% of primary care physicians were aware of SERM therapy as an option for male hypogonadism 7.

As Dr. Mohit Khera, a professor of urology at Baylor College of Medicine, has noted: "We have good evidence that clomiphene and enclomiphene can raise testosterone while preserving fertility, but the average internist has never written a prescription for either one."

This awareness gap is itself an access barrier. A man whose only healthcare touchpoint is a primary care clinic may never hear about enclomiphene, regardless of whether it is the better clinical fit.

State-by-State Compounding Pharmacy Regulations

Access to enclomiphene varies by state because compounding pharmacy regulations are not uniform. Some states restrict 503A pharmacies from shipping compounded medications across state lines. Others have enacted legislation limiting which drugs can be compounded or requiring ingredient-specific oversight. Texas, Florida, and California have large networks of compounding pharmacies and relatively permissive frameworks. States with smaller compounding pharmacy footprints may funnel patients toward 503B outsourcing facilities, which are FDA-registered and can ship nationally but may carry higher prices.

Testosterone enanthate faces no such geographic variability. It is a manufactured, FDA-approved product available at any licensed pharmacy in all 50 states 8.

For patients in rural areas or states with limited compounding infrastructure, this difference in distribution logistics can add days to the supply chain and restrict the pool of available pharmacies. Telehealth platforms partially mitigate this by partnering with 503B facilities that ship direct-to-patient, but transit times and shipping fees ($5 to $15 per order) still apply.

Switching Between the Two: What to Expect

Men sometimes start on one medication and switch to the other as their clinical situation changes. The transition is not symmetric.

Switching from enclomiphene to testosterone enanthate is straightforward. Enclomiphene has a half-life of approximately 10 hours. A man can stop taking it and begin testosterone injections within days. LH and FSH will suppress over the following weeks as exogenous testosterone takes over.

Switching from testosterone enanthate to enclomiphene requires patience. The hypothalamic-pituitary axis needs time to recover from suppression. Many clinicians bridge the transition with a short course of hCG (1,000 to 2 to 000 IU three times weekly for 4 to 6 weeks) to stimulate the testes before introducing enclomiphene. Without this bridge, testosterone levels may dip substantially during the transition, causing symptomatic hypogonadism for weeks. Lab monitoring every 2 to 4 weeks during the switch is standard practice 9.

The cost of switching from testosterone enanthate to enclomiphene, including the hCG bridge, transition labs, and clinical visits, typically adds $400 to $900 in out-of-pocket expense over 6 to 8 weeks.

Making the Cost-Access Decision

The right drug depends on three variables: fertility plans, insurance status, and provider access. A man over 45 with completed family planning, good insurance, and a primary care physician will find testosterone enanthate cheaper, simpler, and immediately available. A man under 35 who wants children, lacks insurance, and uses a telehealth platform may find enclomiphene's higher monthly cost justified by avoided fertility expenses and simpler prescribing logistics. Neither drug is categorically cheaper. The total cost of treating hypogonadism includes the drug, monitoring, add-on therapies, downstream fertility interventions, and the prescribing pathway itself. Men and their clinicians should map all five variables before choosing based on sticker price alone.